Heart Outcomes Prevention Evaluation-3 Passive Follow-Up
Substantial reductions in cholesterol and blood pressure levels for an average of at least five years may lead to sustained long-term benefits, extending beyond the in-trial period, even without further treatments. Participants enrolled in the clinical phase of HOPE-3 will be followed passively (i.e. off study drug) after completion of the trial. During the passive follow-up period, there will be no protocol-mandated therapies and the primary care physicians will determine treatment of all study participants based on their interpretation of the available evidence.
Follow-up will conducted yearly by direct or telephone contact
Occurrence of major CV events
Salim Yusuf, Eva Lonn